April 13, 2015
Questcor Pharmaceuticals Inc. on Monday agreed to pay $38 million to end a consolidated securities class action alleging the company lies about the efficacy of its biggest moneymaker, multiple sclerosis drug Acthar.
November 13, 2014
A California federal judge certified a pension fund and investor class Wednesday in litigation accusing Questcor Pharmaceuticals Inc. of misrepresenting the prospects of its multiple sclerosis drug Acthar.
October 02, 2013
A California federal judge on Tuesday kept alive most of a securities fraud class action against Questcor Pharmaceuticals Inc., finding investors had sufficiently alleged the company had misrepresented the clinical support for its Acthar drug and the stability of insurance reimbursement rates.